LSA
NBIX icon

Leonteq Securities AG’s Neurocrine Biosciences NBIX Stock Holding History

Leonteq Securities AG’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.4K Sell
394
-81
-17% -$12K ﹤0.01% 753
2026
Q1 		$62.6K Buy
475
+69
+17% +$9.15K ﹤0.01% 831
2025
Q4 		$57.6K Sell
406
-74
-15% -$10.7K ﹤0.01% 930
2025
Q3 		$67.4K Sell
480
-582
-55% -$78.9K ﹤0.01% 833
2025
Q2 		$133K Sell
1,062
-188
-15% -$21.6K 0.01% 654
2025
Q1 		$138K Buy
1,250
+408
+48% +$51.7K 0.01% 626
2024
Q4 		$115K Buy
842
+318
+61% +$39.3K 0.01% 657
2024
Q3 		$60.4K Buy
524
+300
+134% +$41.1K ﹤0.01% 717
2024
Q2 		$30.8K Buy
224
+26
+13% +$3.57K ﹤0.01% 859
2024
Q1 		$27.3K Buy
198
+141
+247% +$19.3K ﹤0.01% 875
2023
Q4 		$7.51K Sell
57
-154
-73% -$17.7K ﹤0.01% 1015
2023
Q3 		$23.7K Buy
+211
New +$22.2K ﹤0.01% 929
2023
Q2 		– Sell
-619
Closed -$62.7K – 1282
2023
Q1 		$62.7K Hold
619
– – ﹤0.01% 748
2022
Q4 		$73.9K Sell
619
-1,382
-69% -$162K ﹤0.01% 739
2022
Q3 		$213K Sell
2,001
-399
-17% -$40.5K 0.01% 516
2022
Q2 		$234K Buy
2,400
+1,400
+140% +$129K 0.01% 520
2022
Q1 		$93.8K Sell
1,000
-1,500
-60% -$127K ﹤0.01% 748
2021
Q4 		$213K Sell
2,500
-150
-6% -$13.8K 0.01% 611
2021
Q3 		$254K Buy
2,650
+150
+6% +$14.2K 0.01% 535
2021
Q2 		$243K Sell
2,500
-3,018
-55% -$289K 0.01% 539
2021
Q1 		$537K Buy
5,518
+1,595
+41% +$167K 0.03% 374
2020
Q4 		$376K Buy
+3,923
New +$379K 0.02% 455

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Leonteq Securities AG's NBIX Position: Q2 2026 in Review

Leonteq Securities AG reduced its Neurocrine Biosciences (NBIX) stake by 17% in Q2 2026, selling an estimated $12K and leaving 394 shares worth $66.4K. The position accounts for ﹤0.01% of the portfolio, ranked #753.

Leonteq Securities AG first reported a position in NBIX in Q4 2020 and has held it in 22 quarters since. The position peaked at $537K in Q1 2021. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Leonteq Securities AG held 394 shares of Neurocrine Biosciences worth $66.4K as of Q2 2026.
  • Leonteq Securities AG sold 81 Neurocrine Biosciences shares in Q2 2026, an estimated $12K.
  • Neurocrine Biosciences made up ﹤0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #753 holding.
  • Leonteq Securities AG first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 22 quarters since.
  • Leonteq Securities AG's Neurocrine Biosciences position peaked at $537K in Q1 2021.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.